USP 797 Compliance: What It Means for Patient Safety

USP General Chapter 797 establishes standards for compounding sterile preparations to ensure patient safety. These standards cover personnel training, facility design, environmental monitoring, quality assurance, and beyond-use dating for sterile compounds.

Compliance with USP 797 requires significant investment in facilities, equipment, training, and ongoing monitoring. At NuvexaPharmRx, our sterile compounding suite features ISO Class 5 primary engineering controls within ISO Class 7 buffer rooms, with ISO Class 8 ante-rooms providing proper environmental segregation.

Key USP 797 requirements include: designated cleanroom environments with HEPA filtration, personnel garbing and hand hygiene protocols, viable and non-viable environmental monitoring, media fill testing for sterile technique validation, proper beyond-use dating based on sterility testing, and documentation of all compounding activities.

Our facility undergoes regular third-party audits to verify ongoing compliance with current USP 797 standards, ensuring every sterile preparation meets the highest safety benchmarks.